NCT07865598Not yet recruiting
Low-Intensity Monitoring Nursing After Thrombolysis for Acute Ischemic Stroke
Effect of Low-Intensity Monitoring Frequency After Intravenous Thrombolysis for Acute Ischemic Stroke on Nursing Workload and Missed Nursing Care: A Multicenter, Open-Label, Randomized, Blinded-Endpoint Trial
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This cluster-randomized study compares a lower-frequency post-thrombolysis monitoring pathway with a standard pathway in adults with acute ischemic stroke. The study evaluates nursing workload, nursing care, and clinical safety during the early post-thrombolysis period.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 864 (estimated)
- First submitted
- 27 Sept 2026
- Start date
- Dec 2026
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Shengjing Hospital
- Diseases
- Stroke
- NCT number
- NCT07865598
What you commit to
- Study type: Interventional
- Planned participants: 864
- From Dec 2026 to the primary completion date, 31 Mar 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- or anticipated immediate transfer, dialysis-related transfer, palliative management, or surgery that is incompatible with adherence to the low-intensity monitoring pathway.
Other
- A clear clinical contraindication to low-intensity monitoring, including need for intensive care or prolonged intensive monitoring, severe neurological deficit, early neurological deterioration or substantial risk of deterioration, need for airway support, or need for intravenous treatment unavailable on a general ward;
Who the study is looking for
- Adults aged 18 years or older;
- diagnosis of acute ischemic stroke;
- treatment with intravenous alteplase, tenecteplase, or an equivalent thrombolytic agent as part of clinical care;
- stable vital signs with blood pressure no higher than 180/105 mmHg;
- and mild-to-moderate neurological deficit assessed by a clinician 2 hours after thrombolysis, for example NIHSS less than 10.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.